hotspot -WSS

hotspot

author：Wikipedia 2025-09-08 11:05:00 - browse：44

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

To hear Sarepta CEO Doug Ingram tell it, the results Monday afternoon from a large trial of its gene therapy for Duchenne muscular dystrophy marked a clear medical breakthrough. “A massive win,” he told investors, that could lead to its approval for all patients with the fatal muscle-wasting disease regardless of age.

And yet the rest of the Duchenne community was more cautious in its enthusiasm. The study — the most rigorous test to date of a technology 30 years in the making — had technically failed, as so many had before it.

“It’s extremely frustrating,” said John Brandsema, a pediatric neurologist at Children’s Hospital of Philadelphia who worked on the study. “When you spend decades trying to bring therapies into the clinic for something so severe and just keep missing over and over again.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： CDC recommends rationing of RSV shot due to shortages

Wikipedia

WSS

A clever new way to fix Medicaid and graduate medical education

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

HPV cancer vaccine study demonstrates efficacy

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

Senate panel clears PBM, hopsital reforms

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

entertainment

hotspot

focus

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Readout Newsletter: New research from Sanofi, Regeneron, etc.

Peter Hotez and the public health issue of online harassment

The FDA weighs the risks of candy

Affirmative action in medical school literally saved lives

Readout Newsletter: XBI biotech index, Akero Therapeutics

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Paying for Covid pills will soon shift to insurers

George Santos makes 1st court appearance after pleading not guilty to 13 counts

FDA approves potent Eli Lilly obesity drug, Zepbound

focus

UCSF medical school apologizes for unethical prisoner experiments

Testing for cancer recurrence creates a new limbo for patients

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Study: New antibiotic targets gonorrhea as well as last existing drug

Readout Newsletter: What happened with Sarepta's Duchenne data

The FDA weighs the risks of candy

entertainment

Wikipedia

hotspot

hotspot